Robust ongoing efforts in CAR- T cell therapy, targeting other checkpoint molecules such as TIM-3, LAG-3, and TIGIT, may expand ICI-based therapeutic options for HCC. This evidence concerns the gene LAG3 and hepatocellular carcinoma.